Eli Lilly's LY3437943 is the most anticipated weight loss drug ever studied — a triple GLP-1/GIP/glucagon agonist showing 24% body weight reduction in Phase 2. Here's everything you need to know for 2026.
Retatrutide (development code LY3437943) is an injectable peptide being developed by Eli Lilly. Unlike any currently approved medication, it simultaneously activates three separate metabolic receptors: GLP-1, GIP, and glucagon. This triple mechanism is what makes it so significant — and so different from everything else in the GLP-1 class.
It is administered as a once-weekly subcutaneous injection, similar to semaglutide (Ozempic/Wegovy) and tirzepatide (Mounjaro/Zepbound). As of July 2026, it remains in Phase 3 clinical trials and is not yet available for prescription use.
To understand what makes retatrutide exceptional, you need to understand what each receptor does:
GLP-1 activation slows gastric emptying, reduces appetite, increases feelings of fullness, and improves insulin secretion. This is the same pathway targeted by semaglutide (Ozempic, Wegovy).
GIP activation amplifies insulin release in response to meals and appears to enhance the appetite-suppressing effects of GLP-1 when combined. Tirzepatide (Mounjaro, Zepbound) targets both GLP-1 and GIP and showed better results than semaglutide alone.
This is the key differentiator in retatrutide. Glucagon typically raises blood sugar — which sounds counterproductive — but in the right metabolic context, glucagon receptor activation dramatically accelerates fat burning. The GLP-1 and GIP components keep blood sugar stable while glucagon drives fat oxidation. The result appears to be genuinely synergistic.
The key insight: Each receptor adds to the effect independently. Semaglutide hits one, tirzepatide hits two, retatrutide hits all three. The Phase 2 data suggests this isn't just additive — the combination appears to produce effects beyond what any two receptors achieve alone.
| Drug | Receptors | Avg. Weight Loss | FDA Approved | Available Now |
|---|---|---|---|---|
| Semaglutide Ozempic, Wegovy |
GLP-1 | ~15–17% | Yes | Yes |
| Tirzepatide Zepbound, Mounjaro |
GLP-1 + GIP | ~20–22% | Yes | Yes |
| Retatrutide LY3437943 |
GLP-1 + GIP + Glucagon | ~24% (Phase 2) | No | No — Phase 3 |
| Cagrisema CagriSema |
GLP-1 + Amylin | ~25% (Phase 3) | No | No — Phase 3 |
Based on Phase 2 data, retatrutide's side effect profile is similar to other GLP-1 medications, with gastrointestinal effects being most common — particularly during dose escalation:
Glucagon-specific consideration: Unlike pure GLP-1 drugs, retatrutide's glucagon component may increase heart rate slightly. This was observed in Phase 2 but was generally mild and did not cause significant cardiovascular events in the trial population.
Because retatrutide dramatically reduces appetite — more so than any currently approved drug — what you eat becomes even more important. You will likely eat significantly less. The question is whether what you eat is nutrient-dense enough to support your body during rapid weight loss.
Rapid weight loss on GLP-1 drugs carries a real risk of muscle loss if protein intake is insufficient. With retatrutide, where weight loss speed may exceed tirzepatide, this risk is even more significant. Aim for 0.7–1g of protein per pound of body weight daily. Prioritize:
Whether you're on a current GLP-1 or preparing for retatrutide — ShedPilot's AI builds a personalized nutrition plan around your medication, appetite, protein needs, and goals.
Download Free — App StoreBecause retatrutide significantly suppresses appetite, meals should be small, protein-dense, and nutrient-rich. Three smaller meals with one optional protein snack works well for most people. For a complete day-by-day plan, see our dedicated Retatrutide Meal Plan guide.
For a complete guide with specific meals, recipes, and macro targets, visit: resources.shedpilot.com/retatrutide-meal-plan
ShedPilot was built specifically for people on GLP-1 and peptide journeys. It tracks your medication, monitors protein and macro intake, builds AI-powered meal plans around your reduced appetite, and connects to Instacart for same-day grocery delivery of your meal plan ingredients.
No. Retatrutide is not FDA-approved and is not legally available by prescription anywhere in the world as of 2026. Products sold online claiming to be retatrutide are unregulated research chemicals that have not been tested for human safety at clinical doses. Do not purchase them.
Phase 3 trials are ongoing. If results are positive, Eli Lilly could file an NDA (New Drug Application) with the FDA in 2027, with potential approval following a standard review period. There is no guarantee of approval on any timeline.
If approved with Phase 2-level efficacy, retatrutide would likely become the preferred option for many patients due to superior weight loss. However, individual response, side effects, cost, and insurance coverage will all play a role in which medication any given person uses.
Yes — and it's a good idea. Building a protein-rich, low-processed-food diet now will help maximize results and protect muscle mass whenever you start treatment. Download ShedPilot to build your plan today.
Federal Lawsuits Filed — August 12–24, 2026: Eli Lilly has filed at least six federal lawsuits against a med spa, a compounding pharmacy, and several peptide and chemical vendors accused of selling unapproved versions of retatrutide for human use as a weight loss injection. Retatrutide remains an investigational drug in Phase 3 clinical trials — it is not FDA-approved and cannot be legally compounded or sold for human administration. Lilly's complaints allege these businesses marketed research-use-only retatrutide directly to consumers for weight loss, raising serious safety concerns and potentially interfering with ongoing clinical studies. Legal analysts note the lawsuits signal a broader regulatory crackdown on gray-market incretins. If you are currently being offered retatrutide for weight loss outside of a registered clinical trial, the product has no FDA oversight for dose, purity, or safety, and is now an active enforcement target. The path to legitimate retatrutide access remains through Lilly's Phase 3 trials. Source: Axios / Camino Strategy Group, August 2026.
Pipeline Status — September 2026: Following the landmark TRIUMPH-1 Phase 3 results announced in May 2026 (28.3% average weight loss at 80 weeks — the highest Phase 3 efficacy ever reported for any obesity drug), Eli Lilly has not yet announced a retatrutide NDA submission date. However, analyst consensus expects an NDA filing in late 2026 or early 2027. Multiple remaining TRIUMPH sub-studies (including cardiovascular outcomes and sub-populations) continue to run in parallel. The FDA is simultaneously reviewing CagriSema's NDA (filed December 2025), and analysts project that if both drugs receive approval, the GLP-1 landscape in 2027 would include three meaningfully differentiated weight-loss mechanisms: semaglutide (GLP-1), tirzepatide (GLP-1/GIP), cagrilintide+semaglutide (GLP-1/amylin), and retatrutide (GLP-1/GIP/glucagon). Retatrutide remains an investigational drug — it is not FDA-approved and cannot be legally compounded or obtained outside registered clinical trials.